专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100009992A1 AMPK MODULATORS 有权
标题翻译： AMPK调制器
公开(公告)号：US20100009992A1
公开(公告)日：2010-01-14
申请号：US12365671
申请日：2009-02-04
申请人： Neal C. Birnberg , Hong Liu , Qing Ping Weng , Haibo Shang , Pan Yin , Sharanappa B. Rajur , Hwa-Ok Kim , Paresh D. Salgaonkar , Norton P. Peet
发明人： Neal C. Birnberg , Hong Liu , Qing Ping Weng , Haibo Shang , Pan Yin , Sharanappa B. Rajur , Hwa-Ok Kim , Paresh D. Salgaonkar , Norton P. Peet
IPC分类号： A61K31/437 , A61K31/4985 , A61K31/4375 , A61K31/47 , A61K31/404 , C07D498/04 , C07D471/04 , C07D215/20 , C07D209/12 , A61P35/00 , A61P3/10 , A61P3/04
CPC分类号： C07D498/04 , C07D209/08 , C07D209/12 , C07D209/14 , C07D209/18 , C07D209/42 , C07D215/54 , C07D215/56 , C07D401/04 , C07D403/04 , C07D471/04
摘要： The present invention relates to compounds and pharmaceutically acceptable salts, esters and prodrugs of Formula (I) or (II): which are useful as AMPK modulators effective in treating diabetes, obesity and cancer in a subject.
摘要翻译：本发明涉及式（I）或（II）的化合物和药学上可接受的盐，酯和前药：其可用作对受试者中有效治疗糖尿病，肥胖和癌症的AMPK调节剂。

2. 发明授权

US08273744B2 AMPK modulators 有权
标题翻译： AMPK调制剂
公开(公告)号：US08273744B2
公开(公告)日：2012-09-25
申请号：US12365671
申请日：2009-02-04
申请人： Neal C. Birnberg , Hong Liu , Qing Ping Weng , Haibo Shang , Pan Yin , Sharanappa B. Rajur , Hwa-Ok Kim , Paresh D. Salgaonkar , Norton P. Peet
发明人： Neal C. Birnberg , Hong Liu , Qing Ping Weng , Haibo Shang , Pan Yin , Sharanappa B. Rajur , Hwa-Ok Kim , Paresh D. Salgaonkar , Norton P. Peet
IPC分类号： A01N43/58 , A01N43/42 , A01N43/38 , A61K43/60 , A61K31/44 , A61K31/405 , C07D471/00 , C07D215/00 , C07D209/04
CPC分类号： C07D498/04 , C07D209/08 , C07D209/12 , C07D209/14 , C07D209/18 , C07D209/42 , C07D215/54 , C07D215/56 , C07D401/04 , C07D403/04 , C07D471/04
摘要： The present invention relates to compounds and pharmaceutically acceptable salts, esters and prodrugs of Formula (I) or (II): which are useful as AMPK modulators effective in treating diabetes, obesity and cancer in a subject.
摘要翻译：本发明涉及式（I）或（II）的化合物和药学上可接受的盐，酯和前药：其可用作对受试者中有效治疗糖尿病，肥胖和癌症的AMPK调节剂。

3. 发明授权

US08980895B2 AMPK modulators 有权
标题翻译： AMPK调制剂
公开(公告)号：US08980895B2
公开(公告)日：2015-03-17
申请号：US13571218
申请日：2012-08-09
申请人： Neal C. Birnberg , Hong Liu , Qing Ping Weng , Haibo Shang , Pan Yin , Sharanappa B. Rajur , Hwa-Ok Kim , Paresh D. Salgaonkar , Norton P. Peet
发明人： Neal C. Birnberg , Hong Liu , Qing Ping Weng , Haibo Shang , Pan Yin , Sharanappa B. Rajur , Hwa-Ok Kim , Paresh D. Salgaonkar , Norton P. Peet
IPC分类号： A01N43/58 , A01N43/42 , A01N43/38 , A61K31/44 , A61K31/405 , C07D471/00 , C07D215/00 , C07D209/04 , C07D209/08 , C07D209/14 , C07D209/42 , C07D215/54 , C07D401/04 , C07D403/04 , C07D471/04 , C07D498/04
CPC分类号： C07D498/04 , C07D209/08 , C07D209/12 , C07D209/14 , C07D209/18 , C07D209/42 , C07D215/54 , C07D215/56 , C07D401/04 , C07D403/04 , C07D471/04
摘要： The present invention relates to compounds and pharmaceutically acceptable salts, esters and prodrugs of Formula (I) or (II): which are useful as AMPK modulators effective in treating diabetes, obesity and cancer in a subject.
摘要翻译：本发明涉及式（I）或（II）的化合物和药学上可接受的盐，酯和前药：其可用作对受试者中有效治疗糖尿病，肥胖和癌症的AMPK调节剂。

4. 发明申请

US20120302576A1 AMPK MODULATORS 审中-公开
标题翻译： AMPK调制器
公开(公告)号：US20120302576A1
公开(公告)日：2012-11-29
申请号：US13571218
申请日：2012-08-09
申请人： Neal C. Birnberg , Hong Liu , Qing Ping Weng , Haibo Shang , Pan Yin , Sharanappa B. Rajur , Hwa-Ok Kim , Paresh D. Salgaonkar , Norton P. Peet
发明人： Neal C. Birnberg , Hong Liu , Qing Ping Weng , Haibo Shang , Pan Yin , Sharanappa B. Rajur , Hwa-Ok Kim , Paresh D. Salgaonkar , Norton P. Peet
IPC分类号： A61K31/404 , C07D215/54 , A61K31/47 , C07D498/04 , A61K31/437 , C07D471/04 , A61K31/4375 , C07D209/42 , C07D403/10 , A61K31/501 , C07D401/10 , A61K31/4439 , A61P3/10 , A61P3/04 , A61P35/00 , A61K31/4985 , C07D209/08
CPC分类号： C07D498/04 , C07D209/08 , C07D209/12 , C07D209/14 , C07D209/18 , C07D209/42 , C07D215/54 , C07D215/56 , C07D401/04 , C07D403/04 , C07D471/04
摘要： The present invention relates to compounds and pharmaceutically acceptable salts, esters and prodrugs of Formula (I) or (II): which are useful as AMPK modulators effective in treating diabetes, obesity and cancer in a subject.
摘要翻译：本发明涉及式（I）或（II）的化合物和药学上可接受的盐，酯和前药：其可用作对受试者中有效治疗糖尿病，肥胖和癌症的AMPK调节剂。

5. 发明授权

US5691368A Substituted oxazolidine calpain and/or cathepsin B inhibitors 失效
标题翻译：取代的恶唑烷钙蛋白酶和/或组织蛋白酶B抑制剂
公开(公告)号：US5691368A
公开(公告)日：1997-11-25
申请号：US552139
申请日：1995-12-11
申请人： Norton P. Peet , Shujaath Mehdi , Matthew D. Linnik , Michael R. Angelastro , Hwa-Ok Kim
发明人： Norton P. Peet , Shujaath Mehdi , Matthew D. Linnik , Michael R. Angelastro , Hwa-Ok Kim
IPC分类号： C07D263/06 , A61K31/42 , A61K31/421 , A61K31/535 , A61K31/5377 , A61K38/00 , A61P9/08 , A61P9/10 , A61P25/00 , A61P25/28 , A61P43/00 , C07D263/04 , C07D263/18 , C07K5/062
CPC分类号： C07D263/04
摘要： This invention relates to oxazolidine inhibitors of calpain and/or cathepsin B and to compositions containing them. As inhibitors of calpain and/or cathepsin B, the compounds are useful in the treatment of patients afflicted with acute or chronic neurodegenerative disorders.
摘要翻译：本发明涉及钙蛋白酶和/或组织蛋白酶B的恶唑烷抑制剂以及含有它们的组合物。作为钙蛋白酶和/或组织蛋白酶B的抑制剂，该化合物可用于治疗患有急性或慢性神经变性疾病的患者。

6. 发明授权

US09265734B2 Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors 有权
标题翻译：组合物包括作为HDAC抑制剂的6-氨基己酸衍生物
公开(公告)号：US09265734B2
公开(公告)日：2016-02-23
申请号：US13062030
申请日：2009-09-03
申请人： James R. Rusche , Norton P. Peet , Allen T. Hopper
发明人： James R. Rusche , Norton P. Peet , Allen T. Hopper
IPC分类号： C07C237/04 , A61K31/166 , A61K31/00 , A61K31/16 , C07C235/16 , C07C237/22 , C07C255/57 , C07C311/16 , C07C311/19 , C07C317/44 , C07C323/62 , C07D209/48 , C07D213/30 , C07D231/56 , C07D277/56 , C07D295/14 , C07D307/84 , C07D409/12
CPC分类号： C07C233/80 , A61K31/00 , A61K31/16 , C07C235/16 , C07C237/22 , C07C255/57 , C07C311/16 , C07C311/19 , C07C317/44 , C07C323/62 , C07C2601/02 , C07C2601/14 , C07D209/48 , C07D213/30 , C07D213/81 , C07D217/24 , C07D231/12 , C07D231/56 , C07D237/24 , C07D241/24 , C07D241/44 , C07D271/12 , C07D277/56 , C07D295/14 , C07D295/15 , C07D307/84 , C07D307/85 , C07D333/38 , C07D409/12 , Y02A50/411
摘要： This invention relates to compounds of Formula (I) wherein Cy1, L1, Y, R1, L2, and Ar2 are defined herein, for the treatment of cancers, inflammatory disorders, and neurological conditions.
摘要翻译：本发明涉及式（I）化合物，其中Cy1，L1，Y，R1，L2和Ar2在本文中定义，用于治疗癌症，炎性疾病和神经病症。

7. 发明申请

US20140219995A1 INHIBITORS OF BACTERIAL TYPE III SECRETION SYSTEM 审中-公开
标题翻译：细菌III型分泌系统的抑制剂
公开(公告)号：US20140219995A1
公开(公告)日：2014-08-07
申请号：US14232520
申请日：2012-07-13
申请人： Donald T. Moir , Daniel Aiello , Norton P. Peet , John D. Williams , Matthew Torhan
发明人： Donald T. Moir , Daniel Aiello , Norton P. Peet , John D. Williams , Matthew Torhan
IPC分类号： C07D471/04 , A61K31/36 , C07C235/20 , A61K31/165 , C07D311/58 , A61K31/353 , C07D207/27 , A61K31/4015 , C07D319/08 , C07D235/26 , A61K31/4184 , C07D215/06 , A61K31/47 , C07D217/12 , A61K31/472 , A61K31/437 , A61K45/06 , C07D317/58
CPC分类号： C07D471/04 , A61K31/165 , A61K31/275 , A61K31/343 , A61K31/353 , A61K31/357 , A61K31/36 , A61K31/4015 , A61K31/402 , A61K31/4184 , A61K31/437 , A61K31/47 , A61K31/472 , A61K31/4741 , A61K45/06 , C07C235/20 , C07D207/27 , C07D215/06 , C07D217/12 , C07D235/26 , C07D311/58 , C07D317/58 , C07D319/08 , Y02A50/473 , Y02A50/475 , Y02A50/481 , A61K2300/00
摘要： Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Pseudomonas spp., Yersinia spp., enteropathogenic and enteroinvasive Escherichia coli, and Chlamydia spp. having such type III secretion systems.
摘要翻译：公开了显示抑制由细菌III型分泌系统介导的效应物毒素分泌或易位的能力的有机化合物。所公开的III型分泌系统抑制剂化合物可用于抵抗革兰氏阴性菌如沙门氏菌属，志贺氏菌属，假单胞菌属，耶尔森氏菌属，肠致病性肠炎和肠毒素性大肠杆菌和衣原体属的感染。具有这种III型分泌系统。

8. 发明授权

US06693072B2 Elastase inhibitors 失效
标题翻译：弹性蛋白酶抑制剂
公开(公告)号：US06693072B2
公开(公告)日：2004-02-17
申请号：US09741536
申请日：2000-12-20
申请人： Steven L. Gallion , William A. Metz Jr. , Joseph P. Burkhart , Michael R. Angelastro , Norton P. Peet
发明人： Steven L. Gallion , William A. Metz Jr. , Joseph P. Burkhart , Michael R. Angelastro , Norton P. Peet
IPC分类号： A61K3800
CPC分类号： C07K5/06191 , A61K38/00
摘要： This invention relates to compounds which are inhibitors of elastase, particularly human neutrophil elastase. The inhibitors are short, synthetic peptides in which the P2 moiety is substituted with various nitrogen-containing heterocyclic groups. As inhibitors of human neutrophil elastase, the compounds are useful in the treatment of a patient afflicted with a neutrophil associated inflammatory disease.
摘要翻译：本发明涉及作为弹性蛋白酶抑制剂，特别是人嗜中性粒细胞弹性蛋白酶的化合物。抑制剂是其中P2部分被各种含氮杂环基团取代的短合成肽。作为人嗜中性粒细胞弹性蛋白酶抑制剂，该化合物可用于治疗患有嗜中性粒细胞相关性炎性疾病的患者。

9. 发明授权

US06642231B2 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines 失效
标题翻译： 6,9-二取代的2- [反 - （4-氨基环己基）氨基]嘌呤
公开(公告)号：US06642231B2
公开(公告)日：2003-11-04
申请号：US10178494
申请日：2002-06-24
申请人： Jennifer A. Dumont , Alan J. Bitonti , David R. Borcherding , Norton P. Peet , H. Randall Munson, Jr. , Patrick W. Shum
发明人： Jennifer A. Dumont , Alan J. Bitonti , David R. Borcherding , Norton P. Peet , H. Randall Munson, Jr. , Patrick W. Shum
IPC分类号： C07D47316
CPC分类号： C07D473/00
摘要： The present invention comprises 6-9-Disubstituted 2-[trans-(4-aminocyclohexyl]aminopurines that are useful in inhibiting cyclin dependent kinases, particularly cdk-2. The present invention also provides a method of preventing apoptosis in neuronal cells and a method of inhibiting the development of neoplasms.
摘要翻译：本发明包括可用于抑制细胞周期蛋白依赖性激酶，特别是cdk-2的6-9-二取代的2- [反 - （4-氨基环己基）氨基嘌呤，本发明还提供了一种预防神经元细胞凋亡的方法和方法抑制肿瘤的发展。

10. 发明授权

US06413951B2 20-fluoro-17(20)-vinyl steroids 失效
标题翻译： 20-氟-17（20） - 乙烯基类固醇
公开(公告)号：US06413951B2
公开(公告)日：2002-07-02
申请号：US09886818
申请日：2001-06-21
申请人： Norton P. Peet , Philip M. Weintraub , Joseph P. Burkhart , Cynthia A. Gates
发明人： Norton P. Peet , Philip M. Weintraub , Joseph P. Burkhart , Cynthia A. Gates
IPC分类号： A61K3156
CPC分类号： C07J13/007
摘要： The invention relates to 20&xgr;-fluoropregna-4,17(20)-dien-3-on-21-oic acid ethyl ester, 20&xgr;-fluoro-3&bgr;-hydroxypregna-5,17(20)-dien-21-oic acid ethyl ester, 20&xgr;-fluoro-21-hydroxypregna-4,17 (20)-dien-3-one, 20&xgr;-fluoropregna-5,17(20)-dien-3&bgr;,21-diol and related compounds and to compositions incorporating these compounds, as well as the inhibition of C17,20 lyase, 5&agr;-reductase and C17-hydroxylase, and to the use of these compounds in the treatment of androgen and estrogen mediated or dependent disorders, including benign prostatic hyperplasia, prostate cancer, breast cancer and DHT-mediated disorders such as acne and hirsutism. Treatment of disorders related to the over synthesis of cortisol, for example, Cushing's Syndrome are also included. The treatment of androgen-dependent disorders also includes a combination therapy with known androgen-receptor antagonists, such as flutamide. The compounds of the invention have the following general formulae:
摘要翻译：本发明涉及20和xgr-氟孕烷-4,17（20） - 二烯-21-蓖麻油酸乙酯，20＆xgr-氟-3β-羟基孕烯-5,17（20） - 二烯-21-酸（20） - 二烯-3-酮，20和xgr-氟孕烷-5,17（20） - 二烯-3β，21-二醇及相关化合物，并与掺入这些化合物的组合物以及C17,20裂解酶，5α-还原酶和C17-羟化酶的抑制，以及这些化合物在治疗雄激素和雌激素介导或依赖性疾病（包括良性前列腺增生症，前列腺癌）中的用途，乳腺癌和DHT介导的疾病如痤疮和多毛症。还包括治疗与过度合成皮质醇有关的疾病，例如库欣综合征。雄激素依赖性疾病的治疗还包括与已知的雄激素受体拮抗剂如氟他胺的联合治疗。本发明化合物具有以下通式：

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式